Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 4.224
Filter
1.
BMJ Open ; 14(5): e078105, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38692725

ABSTRACT

OBJECTIVES: Patients receiving chiropractic spinal manipulation (CSM) for low back pain (LBP) are less likely to receive any opioid prescription for subsequent pain management. However, the likelihood of specifically being prescribed tramadol, a less potent opioid, has not been explored. We hypothesised that adults receiving CSM for newly diagnosed radicular LBP would be less likely to receive a tramadol prescription over 1-year follow-up, compared with those receiving usual medical care. DESIGN: Retrospective cohort study. SETTING: US medical records-based dataset including >115 million patients attending academic health centres (TriNetX, Inc), queried 9 November 2023. PARTICIPANTS: Opioid-naive adults aged 18-50 with a new diagnosis of radicular LBP were included. Patients with serious pathology and tramadol use contraindications were excluded. Variables associated with tramadol prescription were controlled via propensity matching. INTERVENTIONS: Patients were divided into two cohorts dependent on treatment received on the index date of radicular LBP diagnosis (CSM or usual medical care). PRIMARY AND SECONDARY OUTCOME MEASURES: Risk ratio (RR) for tramadol prescription (primary); markers of usual medical care utilisation (secondary). RESULTS: After propensity matching, there were 1171 patients per cohort (mean age 35 years). Tramadol prescription was significantly lower in the CSM cohort compared with the usual medical care cohort, with an RR (95% CI) of 0.32 (0.18 to 0.57; p<0.0001). A cumulative incidence graph demonstrated that the reduced incidence of tramadol prescription in the CSM cohort relative to the usual medical care cohort was maintained throughout 1-year follow-up. Utilisation of NSAIDs, physical therapy evaluation and lumbar imaging was similar between cohorts. CONCLUSIONS: This study found that US adults initially receiving CSM for radicular LBP had a reduced likelihood of receiving a tramadol prescription over 1-year follow-up. These findings should be corroborated by a prospective study to minimise residual confounding.


Subject(s)
Analgesics, Opioid , Low Back Pain , Manipulation, Chiropractic , Tramadol , Humans , Low Back Pain/drug therapy , Low Back Pain/therapy , Adult , Female , Retrospective Studies , Tramadol/therapeutic use , Male , Analgesics, Opioid/therapeutic use , Middle Aged , United States , Manipulation, Chiropractic/statistics & numerical data , Young Adult , Adolescent , Drug Prescriptions/statistics & numerical data , Pain Management/methods , Pain Management/statistics & numerical data
2.
Scand J Pain ; 24(1)2024 Jan 01.
Article in English | MEDLINE | ID: mdl-38708610

ABSTRACT

OBJECTIVES: Multimodal pain management is one component in enhanced recovery after surgery protocol. Here we evaluate the efficacy of tramadol-paracetamol in acute postoperative pain and pain outcome at 12 months after spine surgery in randomized, double-blind, placebo-controlled trial. METHODS: We randomized 120 patients undergoing spine surgery to receive, for add-on pain management, two tramadol-paracetamol 37.5 mg/325 mg (n = 61) or placebo tablets (n = 59) twice a day for 5 postoperative days. In the hospital, multimodal pain management consisted of dexketoprofen and oxycodone. After discharge, patients were prescribed ibuprofen 200 mg, maximum 1,200 mg/day. Pain, analgesic use, and satisfaction with pain medication were followed up with the Brief Pain Inventory questionnaire before surgery and at 1 and 52 weeks after surgery. The primary outcome was patients' satisfaction with pain medication 1 week after surgery. RESULTS: At 1 week after surgery, patients' satisfaction with pain medication was similarly high in the two groups, 75% [interquartile range, 30%] in the placebo group and 70% [40%] in the tramadol-paracetamol group (p = 0.949) on a scale: 0% = not satisfied, 100% = totally satisfied. At 1 week, ibuprofen dose was lower in the placebo group 200 mg [1,000] compared to the tramadol-paracetamol group, 800 mg [1,600] (p = 0.016). There was no difference in the need for rescue oxycodone. Patients in the tramadol-paracetamol group had more adverse events associated with analgesics during the first postoperative week (relative risk = 1.8, 95% confidence interval, 1.2-2.6). CONCLUSION: Add-on pain treatment with tramadol-paracetamol did not enhance patients' satisfaction with early pain management after back surgery.


Subject(s)
Acetaminophen , Analgesics, Opioid , Pain, Postoperative , Tramadol , Humans , Pain, Postoperative/drug therapy , Tramadol/administration & dosage , Tramadol/therapeutic use , Double-Blind Method , Acetaminophen/administration & dosage , Acetaminophen/therapeutic use , Male , Female , Middle Aged , Analgesics, Opioid/administration & dosage , Analgesics, Opioid/therapeutic use , Patient Satisfaction , Oxycodone/administration & dosage , Oxycodone/therapeutic use , Analgesics, Non-Narcotic/administration & dosage , Analgesics, Non-Narcotic/therapeutic use , Adult , Spine/surgery , Treatment Outcome , Ibuprofen/administration & dosage , Ibuprofen/therapeutic use , Pain Measurement , Aged
3.
Pak J Pharm Sci ; 37(1): 53-63, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38741400

ABSTRACT

The study focused on the neuroprotective role of Sorghum bicolor and vitamin C in the amelioration of oxidative stress and anxiety-like behavoiur induced by tramadol in male albino rats. The study design involved 7 groups and a control group with 5 male albino rats in each group. Tramadol (40 mg/kg) treatment was administered for 21 days. Tramadol 40mg/kg was administered in all groups. Pretreatment with varying doses of Sorghum bicolor and Vitamin C was done in three of the groups. Behavioral assessment of anxiety and locomotors actions of the groups were compared using Elevated Plus Maze (EPM) and Open Field Test (OFT). In conclusion, Sorghum bicolor and Vitamin C tramadol ameliorated oxidative stress and anxiety-like behaviour induced by tramadol. Pretreatment with Sorghum bicolor or vitamin C (100mg) can also reduced anxiogenic responses in male albino rats that are induced by chronic tramadol use.


Subject(s)
Anxiety , Ascorbic Acid , Behavior, Animal , Oxidative Stress , Sorghum , Tramadol , Animals , Tramadol/pharmacology , Oxidative Stress/drug effects , Male , Ascorbic Acid/pharmacology , Anxiety/prevention & control , Anxiety/chemically induced , Anxiety/drug therapy , Rats , Behavior, Animal/drug effects , Antioxidants/pharmacology , Brain/drug effects , Brain/metabolism , Neuroprotective Agents/pharmacology , Plant Extracts/pharmacology , Rats, Wistar , Analgesics, Opioid/pharmacology , Anti-Anxiety Agents/pharmacology , Maze Learning/drug effects
4.
J Chromatogr A ; 1725: 464875, 2024 Jun 21.
Article in English | MEDLINE | ID: mdl-38678692

ABSTRACT

Ultrasonic-assisted dispersive micro solid phase extraction (UA-DMSPE) is proposed as a fast and easy technique for the extraction and preconcentration of methadone and tramadol from serum samples. Different sorbents including carbon nanotubes, oxidized carbon nanotubes, and TiO2 nanoparticles were compared to extract methadone and tramadol. The best performance was obtained using oxidized carbon nanotubes due to the strong affinity between the drugs and carbon nanotube adsorbents. Final analysis of drugs performed by using gas chromatography-mass spectrometric detection. Different parameters affecting the extraction efficiency, such as the sample volume, amount of adsorbent, desorption solvent type and volume, centrifugation time, and speed were investigated and optimized. The striking features of this technique are correlated to its speed and the small volumes of sample (about 1 mL), desorption solvent (about 50 µL), and adsorbent (about 0.001 g) for analysis of drugs, and finally, milder centrifugation conditions relative to the previously reported adsorbent. The optimal parameters were achieved as follows: pH value was set at 9, the sample volume was adjusted to 1200 µL, the amount of adsorbent used was 1 mg, the extraction time was set at 5 min, and the volume of the desorption solvent was adjusted to 50 µL. The limits of detections (0.5 and 0.8 ng mL-1) and quantifications (1.5 and 2.5 ng mL-1) were obtained for methadone and tramadol, respectively. The developed method also showed good repeatability, relative standard deviation (RSD) of 9.49 % and 7.47 % (n = 5), for the spiked aqueous solution at the concentration level of 10, 50, and 100 ng mL-1 for analytes, and linearity, R ≥ 0.9809. The results showed that UA-DMSPE is a quick, relatively inexpensive, and environmentally friendly alternative technique for the extraction of opiate drugs from serum samples.


Subject(s)
Gas Chromatography-Mass Spectrometry , Limit of Detection , Methadone , Solid Phase Microextraction , Tramadol , Tramadol/blood , Methadone/blood , Gas Chromatography-Mass Spectrometry/methods , Humans , Solid Phase Microextraction/methods , Nanotubes, Carbon/chemistry , Reproducibility of Results , Adsorption , Titanium
8.
BMC Geriatr ; 24(1): 319, 2024 Apr 05.
Article in English | MEDLINE | ID: mdl-38580920

ABSTRACT

BACKGROUND: Tramadol is increasingly used to treat acute postoperative pain among older adults following total hip and knee arthroplasty (THA/TKA). However, tramadol has a complex pharmacology and may be no safer than full opioid agonists. We compared the safety of tramadol, oxycodone, and hydrocodone among opioid-naïve older adults following elective THA/TKA. METHODS: This retrospective cohort included Medicare Fee-for-Service beneficiaries ≥ 65 years with elective THA/TKA between January 1, 2010 and September 30, 2015, 12 months of continuous Parts A and B enrollment, 6 months of continuous Part D enrollment, and no opioid use in the 6 months prior to THA/TKA. Participants initiated single-opioid therapy with tramadol, oxycodone, or hydrocodone within 7 days of discharge from THA/TKA hospitalization, regardless of concurrently administered nonopioid analgesics. Outcomes of interest included all-cause hospitalizations or emergency department visits (serious adverse events (SAEs)) and a composite of 10 surgical- and opioid-related SAEs within 90-days of THA/TKA. The intention-to-treat (ITT) and per-protocol (PP) hazard ratios (HRs) for tramadol versus other opioids were estimated using inverse-probability-of-treatment-weighted pooled logistic regression models. RESULTS: The study population included 2,697 tramadol, 11,407 oxycodone, and 14,665 hydrocodone initiators. Compared to oxycodone, tramadol increased the rate of all-cause SAEs in ITT analyses only (ITT HR 1.19, 95%CLs, 1.02, 1.41; PP HR 1.05, 95%CLs, 0.86, 1.29). Rates of composite SAEs were not significant across comparisons. Compared to hydrocodone, tramadol increased the rate of all-cause SAEs in the ITT and PP analyses (ITT HR 1.40, 95%CLs, 1.10, 1.76; PP HR 1.34, 95%CLs, 1.03, 1.75), but rates of composite SAEs were not significant across comparisons. CONCLUSIONS: Postoperative tramadol was associated with increased rates of all-cause SAEs, but not composite SAEs, compared to oxycodone and hydrocodone. Tramadol does not appear to have a superior safety profile and should not be preferentially prescribed to opioid-naïve older adults following THA/TKA.


Subject(s)
Arthroplasty, Replacement, Hip , Arthroplasty, Replacement, Knee , Tramadol , Humans , Aged , United States/epidemiology , Analgesics, Opioid/adverse effects , Tramadol/adverse effects , Oxycodone/adverse effects , Arthroplasty, Replacement, Knee/adverse effects , Hydrocodone , Retrospective Studies , Arthroplasty, Replacement, Hip/adverse effects , Medicare
9.
Rev Assoc Med Bras (1992) ; 70(3): e20231457, 2024.
Article in English | MEDLINE | ID: mdl-38656013

ABSTRACT

OBJECTIVE: Erector spinae plane block is an updated method than paravertebral block, possessing a lower risk of complications. This study aimed to compare erector spinae plane and paravertebral blocks to safely reach the most efficacious analgesia procedure in laparoscopic cholecystectomy cases. METHODS: The study included 90 cases, aged 18-70 years, classified as American Society of Anesthesiologists I-II, who underwent an laparoscopic cholecystectomy procedure. They were randomly separated into three groups, namely, Control, erector spinae plane, and paravertebral block. No block procedure was applied to Control, and a patient-controlled analgesia device was prepared containing tramadol at a 10 mg bolus dose and a 10-min locked period. The pain scores were recorded with a visual analog scale for 24 h postoperatively. RESULTS: The visual analog scale values at 1, 5, 10, 20, and 60 min at rest and 60 min coughing were found to be significantly higher in Control than in paravertebral block. A significant difference was revealed between Control vs. paravertebral block and paravertebral block vs. erector spinae plane in terms of total tramadol consumption (p=0.006). Total tramadol consumption in the first postoperative 24 h was significantly reduced in the paravertebral block compared with the Control and erector spinae plane groups. CONCLUSION: Sonography-guided-paravertebral block provides sufficient postoperative analgesia in laparoscopic cholecystectomy surgery. Erector spinae plane seems to attenuate total tramadol consumption.


Subject(s)
Cholecystectomy, Laparoscopic , Nerve Block , Pain Measurement , Pain, Postoperative , Tramadol , Humans , Cholecystectomy, Laparoscopic/methods , Middle Aged , Adult , Nerve Block/methods , Male , Female , Pain, Postoperative/prevention & control , Aged , Young Adult , Adolescent , Tramadol/administration & dosage , Analgesics, Opioid/administration & dosage , Treatment Outcome , Paraspinal Muscles/innervation , Analgesia, Patient-Controlled/methods , Time Factors
10.
Rev Assoc Med Bras (1992) ; 70(3): e20230962, 2024.
Article in English | MEDLINE | ID: mdl-38655995

ABSTRACT

OBJECTIVE: A new block, namely, modified thoracoabdominal nerves block through perichondrial approach, is administered below the costal cartilage. We sought to compare the analgesic efficacy of the modified thoracoabdominal nerves block through perichondrial approach block with local anesthetic infiltration at the port sites in an adult population who underwent laparoscopic cholecystectomy. METHODS: Patients who will undergo laparoscopic cholecystectomy were randomized to receive bilateral ultrasound-guided modified thoracoabdominal nerves block through perichondrial approach blocks or local anesthetic infiltration at the port insertion sites. The primary outcome was the total amount of tramadol used in the first 12 h postoperatively. The secondary outcomes were total IV tramadol consumption for the first postoperative 24 h and visual analog scale scores. RESULTS: The modified thoracoabdominal nerves block through perichondrial approach group had significantly less tramadol use in the first 12 h postoperatively (p<0.001). The modified thoracoabdominal nerves block through perichondrial approach group's visual analog scale scores at rest (static) and with movement (dynamic) were significantly lower compared with the port infiltration group (p<0.05). CONCLUSION: Patients who received modified thoracoabdominal nerves block through perichondrial approach block had significantly less analgesic consumption and better pain scores than those who received port-site injections after laparoscopic cholecystectomy.


Subject(s)
Anesthetics, Local , Cholecystectomy, Laparoscopic , Nerve Block , Pain Measurement , Pain, Postoperative , Tramadol , Humans , Cholecystectomy, Laparoscopic/methods , Male , Female , Nerve Block/methods , Pain, Postoperative/prevention & control , Adult , Middle Aged , Tramadol/administration & dosage , Tramadol/therapeutic use , Anesthetics, Local/administration & dosage , Analgesics, Opioid/administration & dosage , Analgesics, Opioid/therapeutic use , Treatment Outcome , Ultrasonography, Interventional/methods
11.
Mol Pain ; 20: 17448069241252385, 2024.
Article in English | MEDLINE | ID: mdl-38631845

ABSTRACT

Preemptive analgesia is used for postoperative pain management, providing pain relief with few adverse effects. In this study, the effect of a preemptive regime on rat behavior and c-fos expression in the spinal cord of the uterine surgical pain model was evaluated. It was a lab-based experimental study in which 60 female Sprague-Dawley rats; eight to 10 weeks old, weighing 150-300 gm were used. The rats were divided into two main groups: (i) superficial pain group (SG) (with skin incision only), (ii) deep pain group (with skin and uterine incisions). Each group was further divided into three subgroups based on the type of preemptive analgesia administered i.e., "tramadol, buprenorphine, and saline subgroups." Pain behavior was evaluated using the "Rat Grimace Scale" (RGS) at 2, 4, 6, 9 and 24 h post-surgery. Additionally, c-fos immunohistochemistry was performed on sections from spinal dorsal horn (T12-L2), and its expression was evaluated using optical density and mean cell count 2 hours postoperatively. Significant reduction in the RGS was noted in both the superficial and deep pain groups within the tramadol and buprenorphine subgroups when compared to the saline subgroup (p ≤ .05). There was a significant decrease in c-fos expression both in terms of number of c-fos positive cells and the optical density across the superficial laminae and lamina X of the spinal dorsal horn in both SD and DG (p ≤ .05). In contrast, the saline group exhibited c-fos expression primarily in laminae I-II and III-IV for both superficial and deep pain groups and lamina X in the deep pain group only (p ≤ .05). Hence, a preemptive regimen results in significant suppression of both superficial and deep components of pain transmission. These findings provide compelling evidence of the analgesic efficacy of preemptive treatment in alleviating pain response associated with uterine surgery.


Subject(s)
Disease Models, Animal , Pain, Postoperative , Proto-Oncogene Proteins c-fos , Rats, Sprague-Dawley , Uterus , Animals , Female , Proto-Oncogene Proteins c-fos/metabolism , Pain, Postoperative/drug therapy , Uterus/surgery , Uterus/drug effects , Anesthesia, General/methods , Analgesia/methods , Tramadol/pharmacology , Tramadol/therapeutic use , Pain Measurement , Rats , Anesthesia, Local/methods , Behavior, Animal/drug effects , Buprenorphine/pharmacology , Buprenorphine/therapeutic use
12.
R I Med J (2013) ; 107(5): 33-37, 2024 May 02.
Article in English | MEDLINE | ID: mdl-38687267

ABSTRACT

OBJECTIVE: To assess the trends in tramadol dispensing among Medicare Part D patients in Rhode Island. METHODS: An analysis was conducted of the Medicare Part D Provider Utilization and Payment Data Public Use File for the years 2013-2021. Chi squared tests were conducted to assess statistical significance of annual changes in proportions. RESULTS: Following tramadol becoming a controlled substance in 2014, the number of dispensed tramadol prescriptions and patients with a tramadol prescription decreased every subsequent year through 2021 (prescriptions: 42,157 to 33,026; patients: 12,654 to 9,653). The percentage of opioid prescriptions that were tramadol increased from 16.32% in 2013 to 21.19% in 2020. CONCLUSION: Tramadol utilization has been decreasing among the Medicare Part D population in Rhode Island while the percentage of opioid dispensings that were tramadol have been increasing. Future studies are needed to assess whether patients utilizing tramadol are at a higher risk for adverse outcomes.


Subject(s)
Analgesics, Opioid , Medicare Part D , Tramadol , Tramadol/therapeutic use , Rhode Island , Humans , Medicare Part D/statistics & numerical data , Analgesics, Opioid/therapeutic use , United States , Drug Prescriptions/statistics & numerical data , Practice Patterns, Physicians'/trends , Practice Patterns, Physicians'/statistics & numerical data , Drug Utilization/trends , Drug Utilization/statistics & numerical data , Aged , Male , Female
13.
J Feline Med Surg ; 26(3): 1098612X231224662, 2024 03.
Article in English | MEDLINE | ID: mdl-38545955

ABSTRACT

OBJECTIVES: The aim of this study was to compare the analgesic efficacy and the effect on physiological variables and behavior of the use of tramadol, methadone and morphine as preoperative analgesia in healthy cats undergoing elective ovariohysterectomy. METHODS: Cats undergoing ovariohysterectomy were randomly assigned to receive one of the following premedication treatments intramuscularly: methadone (0.2 mg/kg; n = 10); morphine (0.2 mg/kg; n = 10); or tramadol (3 mg/kg; n = 10). Induction of anesthesia was done with propofol, and maintenance of anesthesia was done with isoflurane. Intraoperative heart rate, arterial blood pressure, respiratory rate, end-tidal isoflurane concentration and frequency of rescue analgesia (fentanyl 2.5 µg/kg) were compared between groups. Postoperative analgesia was assessed using the UNESP-Botucatu Multidimensional Composite Pain Scale, and perioperative serum glucose, cortisol concentrations and postoperative rescue analgesia were evaluated. RESULTS: Intraoperative rescue analgesia was required in 76.5% of cats at some time during surgery, and 27% of cats required postoperative rescue analgesia up to 6 h after extubation. There were no significant differences between groups with respect to intraoperative and postoperative rescue analgesia, pain scale scores and end-tidal isoflurane concentrations. In the immediate postoperative period, after extubation, most of the patients presented with hypothermia; however, 1-6 h postoperatively, hyperthermia was observed in most of the patients, and was most common in the tramadol group. CONCLUSIONS AND CLINICAL RELEVANCE: Under the conditions of this study, methadone, morphine and tramadol produced satisfactory postoperative analgesia in most of the cats undergoing ovariohysterectomy, and the effects lasted up to 6 h postoperatively. Intraoperative analgesia was not sufficient in most cases. Significant cardiovascular or respiratory effects contraindicating the use of these drugs were not found. Postanesthetic hyperthermia occurred with all opioids studied and was more frequent in the tramadol group.


Subject(s)
Cat Diseases , Isoflurane , Tramadol , Female , Cats , Animals , Tramadol/therapeutic use , Methadone/therapeutic use , Morphine/therapeutic use , Ovariectomy/veterinary , Ovariectomy/methods , Pain, Postoperative/drug therapy , Pain, Postoperative/prevention & control , Pain, Postoperative/veterinary , Hysterectomy/veterinary , Hysterectomy/methods , Analgesics , Analgesics, Opioid/therapeutic use , Cat Diseases/drug therapy , Cat Diseases/surgery
14.
BMJ Open ; 14(3): e080620, 2024 Mar 19.
Article in English | MEDLINE | ID: mdl-38508619

ABSTRACT

INTRODUCTION: Satisfactory management of acute pain remains a major medical challenge despite the availability of multiple therapeutic options including the fixed-dose combination (FDC) drugs. Tramadol and dexketoprofen trometamol (TRAM/DKP) 75/25 mg FDC was launched in 2018 in Asia and is widely used in the management of moderate to severe acute pain. There are limited data on its effectiveness and safety in Asian patients, and therefore, a need to better understand its usage patterns in clinical practice. We aim to understand the usage pattern of TRAM/DKP FDC, its effectiveness and tolerability in patients with moderate to severe acute pain in Asia. METHODS AND ANALYSIS: REKOVER is a phase-IV, multicountry, multicentre, prospective, real-world observational study. A total of 750 postsurgical and non-surgical patients (male and female, aged 18-80 years) will be recruited from 13 tertiary-care hospitals (15 sites) in Singapore, Thailand, the Philippines and Malaysia. All patients prescribed with TRAM/DKP FDC and willing to participate in the study will be enrolled. The recruitment duration for each site will be 6 months. The severity of pain will be collected using Numeric Pain Rating Scale through the treatment period from day 1 to day 5, while satisfaction with the treatment will be evaluated using Patient Global Evaluation Scale at the end of treatment. Any adverse event reported during the study duration will be recorded for safety analysis (up to day 6). The study data will be entered into the ClaimIt portal and mobile application (app) (ObvioHealth, USA). All the inpatient data will be entered into the portal by the study site and for outpatient it will be done by patients through an app. ETHICS AND DISSEMINATION: The study has been approved by the local ethics committee from each study sites in Singapore, Thailand, the Philippines and Malaysia. Findings will be disseminated through local and global conference presentations, publications in peer-reviewed scientific journals and continuing medical education.


Subject(s)
Acute Pain , Ketoprofen/analogs & derivatives , Tramadol , Tromethamine , Humans , Male , Female , Tramadol/therapeutic use , Acute Pain/drug therapy , Prospective Studies , Pain, Postoperative/drug therapy , Double-Blind Method , Registries , Thailand , Observational Studies as Topic , Drug Combinations
15.
J Zoo Wildl Med ; 55(1): 86-91, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38453491

ABSTRACT

The objective of this study was to determine the pharmacokinetics of two orally administered doses of tramadol (1 mg/kg and 5 mg/kg) and its metabolite, O-desmethyltramadol (M1) in giant tortoises (Chelonoidis vandenburghi, Chelonoidis vicina). Eleven giant tortoises (C. vandenburghi, C. vicina) received two randomly assigned, oral doses of tramadol (either 1 mg/kg or 5 mg/kg), with a washout period of 3 wk between each dose. The half-life (t½) of orally administered tramadol at 1 mg/kg and 5 mg/kg was 11.9 ± 4.6 h and 13.2 ± 6.1 h, respectively. After oral administration of tramadol at 1 mg/kg and 5 mg/kg, the maximum concentration (Cmax) was 125 ± 69 ng/ml and 518 ± 411 ng/ml, respectively. There were not enough data points to determine pharmacokinetic (PK) parameters for the M1 metabolite from either dose. Tramadol administered orally to giant tortoises at both doses provided measurable plasma concentrations of tramadol for approximately 48 h with occasional transient sedation. Oral tramadol at 5 mg/kg, on average, achieves concentrations of >100 ng/ml, the reported human therapeutic threshold, for 24 h. Based on the low levels of M1 seen in this study, M1 may not be a major metabolite in this taxon.


Subject(s)
Tramadol , Turtles , Animals , Administration, Oral , Analgesics, Opioid , Area Under Curve , Half-Life , Tramadol/pharmacokinetics , Tramadol/analogs & derivatives , Turtles/metabolism
16.
J Pharm Biomed Anal ; 243: 116109, 2024 Jun 15.
Article in English | MEDLINE | ID: mdl-38518458

ABSTRACT

An innovative ecofriendly high-performance thin layer chromatographic (HPTLC) method with spectrophotometric detection for simultaneous determination of Tramadol (TMD), Tapentadol (TAP), and Venlafaxine (VEN) in seized dosage forms was presented. Our method was conducted to achieve separation following the optimal conditions: pre-coated silica gel plates using a green mobile phase (heptane: acetone: ammonia, 7:3:0.5 v/v), with absorbance scanning at 272 nm. The validation of the method was done following International Conference on Harmonization (ICH) guidelines, demonstrates linearity, accuracy, precision, selectivity, robustness, and system suitability. Separation was achieved with a detection limit of 0.34, 0.16, and 0.084 (ug/band) for TMD, TAP, and VEN, respectively, the method successfully analyzes seized samples. Trueness is confirmed through a high degree of similarity between HPTLC and gas chromatography results. The study's ecofriendly approach, simplicity, and selectivity position it as a promising method for efficient, on-site monitoring of seized samples.


Subject(s)
Tramadol , Tapentadol , Venlafaxine Hydrochloride , Chromatography, Thin Layer/methods , Pharmaceutical Preparations , Reproducibility of Results
17.
Med J Aust ; 220(6): 315-322, 2024 Apr 01.
Article in English | MEDLINE | ID: mdl-38522006

ABSTRACT

OBJECTIVES: To evaluate the impact of the tightened Pharmaceutical Benefits Scheme (PBS) prescribing rules for immediate release (IR) and controlled release (CR) opioid medicines (1 June 2020), which also eliminated repeat dispensing without authorisation for codeine/paracetamol and tramadol IR and introduced half-pack size item codes for IR formulations. DESIGN, SETTING: Population-based interrupted time series analysis of PBS dispensing data claims for a 10% sample of PBS-eligible residents and IQVIA national opioid medicine sales data (PBS-subsidised and private prescriptions), 28 May 2018 - 6 June 2021. MAIN OUTCOME MEASURES: Mean amount of PBS-subsidised opioid medicines dispensed per day and mean overall amount sold per day - each expressed as oral morphine equivalent milligrams (OME) - overall, by formulation type (IR, CR), and by specific formulation. RESULTS: During the twelve months following the PBS changes, daily PBS-subsidised opioid medicine dispensing was 81 565 OME lower (95% CI, -106 146 to -56 984 OME) than the mean daily level for 2018-20, a decline of 3.8% after adjusting for the pre-intervention trend; the relative reduction was greater for IR (8.4%) than CR formulations (2.6%). Total daily sales of all, IR formulation, and CR formulation opioid medicines did not change significantly after the PBS changes. Repeat dispensing of prescriptions comprised 7.4% of PBS-subsidised opioid dispensing before 1 June 2020, and 1.3% after the changes. Half-pack sizes comprised 8.4% of PBS-subsidised IR opioid medicine dispensing and 2.8% of all opioid medicines sold in the twelve months after the PBS changes. CONCLUSIONS: The introduction of new PBS rules for subsidised opioid medicines was followed by a decline in PBS-subsidised dispensing. Some people may have bypassed the new restrictions by switching to private prescriptions, but our findings suggest that opioid medicine use in Australia declined as a result of the new restrictions.


Subject(s)
Opioid-Related Disorders , Tramadol , Humans , Analgesics, Opioid/therapeutic use , Interrupted Time Series Analysis , Opioid-Related Disorders/drug therapy , Drug Prescriptions , Australia , Delayed-Action Preparations/therapeutic use , Practice Patterns, Physicians'
18.
J Coll Physicians Surg Pak ; 34(3): 348-350, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38462873

ABSTRACT

Serratus posterior superior intercostal plane block (SPSIPB) is a novel technique that provides analgesia in shoulder, hemithorax and in the back of the neck. In this study, the efficacy of this block on postoperative pain and quality of recovery is reported in ten consecutive patients who had undergone reduction mammoplasty. Blocks were performed bilaterally with 30 ml 0.25 % bupivacaine for each side, at the end of surgery. Cumulative tramadol consumption and numerical rating scale (NRS) scores during rest (static) and coughing (dynamic) were assessed within the first postoperative 24 hours. Mean total tramadol consumption was 39 ±9.94 mg. NRS scores above 4 were observed in 5 patients in the dynamic NRS assessment at the postoperative 1st hour, while static and dynamic NRS scores were ≤4 at other durations. SPSIPB may play a part in postoperative multimodal analgesia following mammoplasty in the future and may reduce total analgesic consumption. Key Words: Serratus posterior superior intercostal plane block, Reduction mammoplasty, Breast surgery, Postoperative analgesia.


Subject(s)
Mammaplasty , Tramadol , Humans , Tramadol/therapeutic use , Intermediate Back Muscles , Pain, Postoperative/drug therapy , Mammaplasty/adverse effects , Analgesics , Ultrasonography, Interventional
19.
Drug Ther Bull ; 62(3): 36, 2024 Feb 28.
Article in English | MEDLINE | ID: mdl-38302286

ABSTRACT

Overview of: Danbury G Susan Gladstone: Prevention of future deaths report [online], 2023. Available: https://www.judiciary. uk/​prevention-​of-​future-​death-​reports/​susan-​gladstone-​prevention-​offuture-​deaths-​report/ [Accessed 8 January 2024].


Subject(s)
Tramadol , Warfarin , Humans , Warfarin/adverse effects , Tramadol/adverse effects , Anticoagulants/adverse effects , Analgesics, Opioid
20.
Bioanalysis ; 16(6): 363-374, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38380641

ABSTRACT

Background: This study aims to determine the concentrations of tramadol in earwax (µg/g) and urine (µg/ml) samples taken from postoperative patients, to evaluate the sensitivity of earwax (cerumen) as an alternative analyte and compare it with the findings in urine samples. Results: The results indicated that tramadol concentrations in earwax samples were averaged 45.08 µg/g (range: 13.5-107.7 µg/g), whereas tramadol concentrations in urine samples were averaged 4.97 µg/ml (range: 1.57-10.11 µg/ml). There were significant differences when comparing age groups, duration and sex between earwax and urine samples (p < 0.05). Conclusion: Despite the significant differences between earwax and urine samples, earwax can be used as a bioindicator of tramadol detection.


Subject(s)
Body Fluids , Tramadol , Humans , Cerumen
SELECTION OF CITATIONS
SEARCH DETAIL
...